Kidney transplant drug switch aims to reduce Long-Term risks

NCT ID NCT00811915

Terminated Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether switching kidney transplant patients from tacrolimus to sirolimus (both with mycophenolate mofetil) could reduce long-term complications like kidney damage, diabetes, and cancer. It involved 65 stable transplant recipients between 12 and 36 months after surgery. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sirolimus (Rapamune)
What this could lead to: If successful, switching to sirolimus could lower the risk of long-term kidney damage, new diabetes, and skin cancer after a kidney transplant.
What could go wrong: This trial was terminated early with only 65 participants, so results are limited. The switch may cause rejection or other side effects, and findings may not apply to all transplant patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANTATION

Contacts and locations

Locations

UHAmiens

Amiens, France
UHAngers

Angers, 49933, France
UHCaen

Caen, 14000, France
UHLimoges

Limoges, France
UHNecker

Paris, 75015, France
UHRennes

Rennes, 35000, France
UHRouen

Rouen, 76000, France
UHTours

Tours, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.